| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5789379 | TAKEDA PHARMS USA | Glucagon-like peptide-2 analogs |
Apr, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5789379 (Pediatric) | TAKEDA PHARMS USA | Glucagon-like peptide-2 analogs |
Oct, 2020
(3 years ago) | |
| US7056886 | TAKEDA PHARMS USA | GLP-2 formulations |
Sep, 2022
(1 year, 7 months ago) | |
|
US7056886 (Pediatric) | TAKEDA PHARMS USA | GLP-2 formulations |
Mar, 2023
(1 year, 1 month ago) | |
| US9539310 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US7847061 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9993528 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9572867 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9974835 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9592273 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9592274 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9555079 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9987334 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9981016 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9981014 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9974837 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9968658 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9987335 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9545435 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9968655 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9060992 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9545434 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
| US9968656 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(1 year, 6 months from now) | |
|
US9545435 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9060992 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592274 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9592273 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9572867 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987335 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9993528 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9545434 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9555079 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US7847061 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981016 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968658 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974835 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9974837 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968656 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9968655 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9987334 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9981014 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
|
US9539310 (Pediatric) | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
May, 2026
(2 years from now) | |
Gattex Kit is owned by Takeda Pharms Usa.
Gattex Kit contains Teduglutide Recombinant.
Gattex Kit has a total of 42 drug patents out of which 4 drug patents have expired.
Expired drug patents of Gattex Kit are:
- US5789379*PED
- US7056886
- US7056886*PED
- US5789379
Gattex Kit was authorised for market use on 21 December, 2012.
Gattex Kit is available in powder;subcutaneous dosage forms.
Gattex Kit can be used as treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
Drug patent challenges can be filed against Gattex Kit from 22 June, 2019.
The generics of Gattex Kit are possible to be released after 16 May, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-240) | May 16, 2026 |
| Orphan Drug Exclusivity(ODE-37) | Dec 21, 2019 |
| Pediatric Exclusivity(PED) | Jun 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient
NCE-1 date: 22 June, 2019
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER;SUBCUTANEOUS
GATTEX KIT family patents
